Literature DB >> 10193727

The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics.

S P Marso1, S G Ellis, M Tuzcu, P L Whitlow, I Franco, R E Raymond, E J Topol.   

Abstract

OBJECTIVES: The aims of this study were to compare mortality and clinical events following percutaneous coronary intervention (PCI) between nondiabetics and diabetics with and without proteinuria.
BACKGROUND: Diabetics have increased rates of late myocardial infarction, repeat revascularization and mortality when compared with nondiabetics following PCI. Proteinuria is a marker for diabetic nephropathy and potentially a surrogate marker for advanced atherosclerosis. It is unknown if proteinuria is a predictor of outcome in diabetics following PCI.
METHODS: We performed an observational study of 2,784 patients who underwent PCI at the Cleveland Clinic between January 1993 and December 1995. There were 2,247 nondiabetics and 537 diabetics with urinalysis and follow-up data available (proteinuria n = 217, nonproteinuria n = 320). The diabetic proteinuria group was further prospectively stratified into low concentration (n = 182) and high concentration (n = 35). The end points were all-cause mortality and the composite end point of death, nonfatal myocardial infarction (MI) and need for revascularization.
RESULTS: The mean follow-up time was 20.2 months. The two-year mortality rate was 7.3% and 13.5% for nondiabetics and diabetics, respectively (p < 0.001). The two-year mortality rate was 9.1% and 20.3% for the nonproteinuria and proteinuria groups, respectively (p < 0.001). There was a graded increase in mortality comparing the diabetic group. The two-year mortality rate was 9.1%, 16.2% and 43.1% for the nonproteinuria, low concentration and high concentration groups, respectively (p < 0.001). The difference in survival between the nondiabetic and nonproteinuric diabetics was not significant (p = 0.8).
CONCLUSIONS: The presence of proteinuria is the key determinant of risk following PCI for diabetics. Diabetics without evidence of proteinuria have similar survival compared with nondiabetics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193727     DOI: 10.1016/s0735-1097(99)00035-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  The CARDia trial protocol.

Authors:  D Smith
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

2.  Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting in Patients with Diabetic Nephropathy and Left Main Coronary Artery Disease.

Authors:  Hsin-Ru Li; Chiao-Po Hsu; Shih-Hsien Sung; Chun-Che Shih; Shing-Jong Lin; Wan-Leong Chan; Cheng-Hsueh Wu; Tse-Min Lu
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

Review 3.  Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.

Authors:  Yan-Huan Feng; Ping Fu
Journal:  Chin Med J (Engl)       Date:  2016-01-05       Impact factor: 2.628

Review 4.  Dual blockade of the renin-angiotensin system in diabetic nephropathy.

Authors:  Mordchai Ravid
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

5.  Association of estimated glomerular filtration rate and proteinuria with all-cause mortality in community-based population in China: A Result from Kailuan Study.

Authors:  Jianwei Wu; Jiaokun Jia; Zhaoxia Li; Hua Pan; Anxin Wang; Xiuhua Guo; Shouling Wu; Xingquan Zhao
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.